You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Second discussion paper: Improving access to Consumer Medicines Information (CMI) and Product Information (PI)
This consultation closed on 30 March 2007.
In April 2005, the Therapeutic Goods Administration (TGA) released a Discussion Paper on the most appropriate means for improving consumer and professional access to web based copies of up-to-date Consumer Medicine Information (CMI) and Product Information (PI).
Following the release of the Initial Discussion Paper, the TGA held forums in Sydney and Melbourne to discuss the issues raised in the paper and to seek stakeholder view on options for improving consumer and professional access to web based copies of up-to-date CMI and PI. Written submissions were also received from a wide range of stakeholders.
As a result of the very valuable feedback provided on the Initial Discussion Paper, the TGA is now able to provide more detail about each of the options discussed and report on the outcome of the consultations.
The purpose of this Second Discussion Paper is to seek stakeholder views on some revised options including the TGA's preferred option. As the feedback from this consultation will also flow through into the development of practices for the Australia New Zealand Therapeutic Products Authority (ANZTPA) and joint regulatory scheme, feed back is sought from both New Zealand and Australian stakeholders.
- Glossary of terms and acronyms used
- Summary of outcomes of initial consultations
- Chapter 1: Stakeholder views on objectives and scope of review
- Chapter 2: Stakeholder and TGA views on options proposed in Initial Discussion Paper
- Chapter 3: Implementation Issues
- Attachment A: Background information about PI and CMI